Study provides preliminary evidence for a neurocognitive subtype of PTSD
A major obstacle in understanding and treating posttraumatic stress disorder (PTSD) is its clinical and neurobiological heterogeneity. In order to better treat the condition and address this barrier, the field has become increasingly interested in identifying subtypes of PTSD based on dysfunction in neural networks alongside cognitive impairments that may underlie the development and maintenance of symptoms.
VA and BU researchers have now found a marker of PTSD in brain regions associated with emotional regulation. This marker was strongest in those with clinically impaired executive function or the ability to engage in complex goal-directed behavior, explained corresponding author Audreyana Jagger-Rickels, PhD, a post-doctoral scientist in the Boston Attention and Learning Lab (BALLAB) at the VA Boston Healthcare System.
Boston University School of Medicine
(Boston)–A major obstacle in understanding and treating posttraumatic stress disorder (PTSD) is its clinical and neurobiological heterogeneity. In order to better treat the condition and address this barrier, the field has become increasingly interested in identifying subtypes of PTSD based on dysfunction in neural networks alongside cognitive impairments that may underlie the development and maintenance of symptoms.
VA and BU researchers have now found a marker of PTSD in brain regions associated with emotional regulation. “This marker was strongest in those with clinically impaired executive function or the ability to engage in complex goal-directed behavior,” explained corresponding author Audreyana Jagger-Rickels, PhD, a post-doctoral scientist in the Boston Attention and Learning Lab (BALLAB) at the VA Boston Healthcare System.
Share this article
Share this article
SUZHOU, China, April 20, 2021 /PRNewswire/ Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of its IND for TST005 from US FDA for initiating Phase I clinical trial of its bi-functional anti-PD-L1/TGF-β antibody.
TST005, is a bi-functional anti-PD-L1 and TGF-β trap fusion protein designed to simultaneously target two immuno-suppressive pathways, transforming growth factor -β (TGF-β) and programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system. TST005 consists of a high affinity PD-L1 antibody fused with an engineered TGF-β Receptor Type II protein in its C-terminal. TST005 lacks FcR binding activity and thus has reduced FcR mediated killing of PD-L1 expressing effector T cells. TST005 s high P
Share this article
Share this article
NEW YORK, April 7, 2021 /PRNewswire/ Today, before the National Kidney Foundation s 2021 Spring Clinicals Meetings of thousands of kidney health professionals, hundreds of studies from the last year were presented including three studies considered late-breaking research papers.
The presentations were made at the virtual presentation at the annual Spring Clinical Meetings, which was held virtually for the second year due to COVID-19 restriction. The event is a chance for investigators to share their findings with professionals who attend the conference, which is one of the most respected gatherings of kidney professionals in the United States.
Cutting-edge Research Unveiled at National Kidney Foundation s Annual Professional Meeting prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.